Process Validation Should Take Lifecycle Approach, European Commission Says

International Pharmaceutical Regulatory Monitor
A A
Drugmakers should clearly define their validation activities in a validation master plan that accounts for the lifecycle of a product and related plant equipment, the European Commission says.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor

Buy This Article Now

Add this article to your cart for $40.00